Windows LiveWindows Live™
 
 
柔荣's profile不孕不育新进展（英文）PhotosBlogListsMore Tools Help

Blog
    6/22/2009

    Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial

    Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial

    Daniela Romualdi, M.D.a, Maddalena Giuliani, M.D.a, Francesca Cristello, M.D.a, Anna Maria Fulghesu, M.D.c, Luigi Selvaggi, M.D.a, Antonio Lanzone, M.D.ab, Maurizio Guido, M.D., Ph.D.aCorresponding Author Informationemail address

    Received 1 October 2008; received in revised form 14 January 2009; accepted 19 January 2009. published online 06 March 2009.
    Corrected Proof

    Objective

    To investigate metformin effects on the endocrine-metabolic parameters and ovarian morphology in normoinsulinemic women with polycystic ovary syndrome (PCOS).

    Design

    Randomized double-blind study.

    Setting

    Operative Division of Endocrinological Gynecology, Università Cattolica del Sacro Cuore.

    Patient(s)

    Twenty-eight normal-weight normoinsulinemic PCOS women.

    Intervention(s)

    Patients were randomized to receive metformin 500 mg twice a day (group A, 15 subjects) or placebo (group B, 13 subjects) for 6 months. Ultrasonographic pelvic exams, hormonal and lipid features, and oral glucose tolerance test were performed at baseline and after 3 and 6 months of treatment.

    Main Outcome Measure(s)

    Hormonal and glycoinsulinemic assessment, ovarian ultrasound appearance.

    Result(s)

    Glycoinsulinemic assessment remained unvaried in both groups. About 70% of patients in group A experienced a restoration of menstrual cyclicity. Metformin significantly decreased testosterone levels at 3 and 6 months) and 17-hydroxyprogesterone levels at 6 months, and improved hirsutism score at 6 months. No clinical or hormonal modifications occurred in group B. Metformin, but not placebo, reduced ovarian volume and stromal/total area ratio at 3 and 6 months.

    Conclusion(s)

    Metformin seems to improve the menstrual pattern and ultrasonographic ovarian features in normoinsulinemic PCOS women. These effects seem to be, at least in part, independent of the insulin-lowering properties of the drug.

    10:16:21 PM | Blog it

    Comments

    Please wait...
    Sorry, the comment you entered is too long. Please shorten it.
    You didn't enter anything. Please try again.
    Sorry, we can't add your comment right now. Please try again later.
    To add a comment, you need permission from your parent. Ask for permission
    Your parent has turned off comments.
    Sorry, we can't delete your comment right now. Please try again later.
    You've exceeded the maximum number of comments that can be left in one day. Please try again in 24 hours.
    Your account has had the ability to leave comments disabled because our systems indicate that you may be spamming other users. If you believe that your account has been disabled in error please contact Windows Live support.
    Complete the security check below to finish leaving your comment.
    The characters you type in the security check must match the characters in the picture or audio.

    To add a comment, sign in with your Windows Live ID (if you use Hotmail, Messenger, or Xbox LIVE, you have a Windows Live ID). Sign in


    Don't have a Windows Live ID? Sign up

    Trackbacks

    The trackback URL for this entry is:
    http://lrrivf.spaces.live.com/blog/cns!C77791AAB4F59DF4!201.trak
    Weblogs that reference this entry
    • None